Details of the Drug Combination

General Information of Drug Combination (ID: DC1OFN0)

Drug Combination Name
F901318 Caspofungin
Indication
Disease Entry Status REF
Pulmonary Aspergillosis - Invasive Phase 1 [1]
Component Drugs F901318   DM2CUS0 Caspofungin   DMGQIPT
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of F901318
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Phase 2 [2]
F901318 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) TTTSUI2 G5EB61_EMENI Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Caspofungin
Disease Entry ICD 11 Status REF
Candidiasis 1F23 Approved [3]
Fungal infection 1F29-1F2F Approved [4]
Mycoses 1F2Z Approved [3]
Mycosis fungoides 2B01 Approved [3]
Candidemia 1F23.3Y Investigative [3]
Esophageal candidiasis N.A. Investigative [3]
Caspofungin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fungal 1,3-beta-glucan synthase (Fung GSC2) TT0SFXH FKS2_YEAST Modulator [6]
------------------------------------------------------------------------------------
Caspofungin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02856178) Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
2 ClinicalTrials.gov (NCT03583164) Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS). U.S. National Institutes of Health.
3 Caspofungin FDA Label
4 Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
5 Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.